Mortality and Other Important Diabetes-Related Outcomes With Insulin vs Other Antihyperglycemic Therapies in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
CONTEXT: The safety of insulin in the treatment of type 2 diabetes mellitus (T2DM) has recently undergone scrutiny. OBJECTIVE: The objective of the study was to characterize the risk of adverse events associated with glucose-lowering therapies in people with T2DM. DESIGN AND SETTING: This was a retrospective cohort study using data from the UK General Practice Research Database, 2000-2010. PATIENTS: Patients comprised 84 622 primary care patients with T2DM treated with one of five glucose-lowering regimens: metformin monotherapy, sulfonylurea monotherapy, insulin monotherapy, metformin plus sulfonylurea combination therapy, and insulin plus metformin combination therapy. There were 105 123 exposure periods. MAIN OUTCOME MEASURES: The risk of the first major adverse cardiac event, first cancer, or mortality was measured. Secondary outcomes included these individual constituents and microvascular complications. RESULTS: In the same model, and using metformin monotherapy as the referent, the adjusted hazard ratio (aHR) for the primary end point was significantly increased for sulfonylurea monotherapy (1.436, 95% confidence interval [CI] 1.354-1.523), insulin monotherapy (1.808, 95% CI 1.630-2.005), and insulin plus metformin (1.309, 95% CI 1.150-1.491). In glycosylated hemoglobin/morbidity subgroups, patients treated with insulin monotherapy had aHRs for the primary outcome ranging from 1.469 (95% CI 0.978-2.206) to 2.644 (95% CI 1.896-3.687). For all secondary outcomes, insulin monotherapy had increased aHRs: myocardial infarction (1.954, 95% CI 1.479-2.583), major adverse cardiac events (1.736, 95% CI 1.441-2.092), stroke (1.432, 95% CI 1.159-1.771), renal complications (3.504, 95% CI 2.718-4.518), neuropathy (2.146, 95% CI 1.832-2.514), eye complications (1.171, 95% CI 1.057-1.298), cancer (1.437, 95% CI 1.234-1.674), or all-cause mortality (2.197, 95% CI 1.983-2.434). When compared directly, aHRs were higher for insulin monotherapy vs all other regimens for the primary end point and all-cause mortality. CONCLUSIONS: In people with T2DM, exogenous insulin therapy was associated with an increased risk of diabetes-related complications, cancer, and all-cause mortality. Differences in baseline characteristics between treatment groups should be considered when interpreting these results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Insulin therapy has raised similar concerns with respect to cardiovascular safety and has been associated with adverse cardiovascular outcomes and mortality in observational studies.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [206]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
Standards of Medical Care in Diabetes
Power, D. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,673
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125 · cited 8×
“670 Currie et al Clinical Outcomes of Treatment With Insulin J Clin Endocrinol Metab, February 2013, 98(2):668–677”
InfluentialThe National Institute for Clinical Excellence
(2001) · Nursing Management · doi:10.7748/nm.8.2.39.s15 · Cited by 3,876
Basevi, V., Di Mario, S., Morciano, C., Nonino, F., & Magrini, N. (2011) · Diabetes Care · doi:10.2337/dc11-0174 · Cited by 3,055
Standards of medical care in diabetes—2011
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s011 · Cited by 2,880
Basal insulin and cardiovascular and other outcomes in dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636 · cited 1×
“3 mmol/L with insulin glargine vs usual care over an estimated five-year treatment period in people with established cardiovascular disease coupled with glucose intolerance or early T2DM (29).”
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J., Poole, C. D., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1440-6 · Cited by 1,124 · cited 2×
“Indeed, endogenous hyperinsulinemia has been linked to an increase in cancer incidence in people without diabetes (30), whereas epidemiological data have linked exogenous insulin therapy with an increased cancer incidence in people with T2DM (22).”
BackgroundSelf-citationGerstein, H. C., Miller, M., & Byington, R. P. (2010) · Cited by 981
Laakso, M., Edelman, S. V., Brechtel, G., & Baron, A. D. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114644 · Cited by 930
Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study
Currie, C. J., Peters, J. R., Tynan, A., Evans, M., Heine, R. J., Bracco, O. L., Zagar, T., & Poole, C. D. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61969-3 · Cited by 874 · cited 1×
“Similarly, in an epidemiological study of people with T2DM treated in UK primary care, those treated with insulin had a 50% increased mortality compared with those managed with a combination of metformin plus sulfonylurea (14).”
Self-citationMalmberg, K., Norhammar, A., Wedel, H., & Rydén, L. (1999) · Circulation · doi:10.1161/01.cir.99.20.2626 · Cited by 847
Nitric oxide release accounts for insulin's vascular effects in humans.
Scherrer, U., Randin, D., Vollenweider, P., Vollenweider, L., & Nicod, P. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117621 · Cited by 756
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetologia · doi:10.1007/s00125-008-1157-y · Cited by 712
Validity of diagnostic coding within the General Practice Research Database: a systematic review
Khan, N. F., Harrison, S. E., & Rose, P. W. (2010) · British Journal of General Practice · doi:10.3399/bjgp10x483562 · Cited by 685
Angiolillo, D. J., Bernardo, E., Ramírez, C., Costa, M. A., Sabaté, M., Jimenez-Quevedo, P., Hernández, R., Moreno, R., Escaned, J., Alfonso, F., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.03.038 · Cited by 310
Hashimoto, J., & Ito, S. (2011) · Hypertension · doi:10.1161/hypertensionaha.111.177469 · Cited by 259
Smooke, S., Horwich, T. B., & Fonarow, G. C. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.07.005 · Cited by 196
The impact of diabetes on survival following breast cancer
Lipscombe, L. L., Goodwin, P. J., Zinman, B., McLaughlin, J. R., & Hux, J. E. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9654-0 · Cited by 176 · cited 1×
“Indeed, endogenous hyperinsulinemia has been linked to an increase in cancer incidence in people without diabetes (30), whereas epidemiological data have linked exogenous insulin therapy with an increased cancer incidence in people with T2DM (22).”
BackgroundBowker, S. L., Yasui, Y., Veugelers, P., & Johnson, J. A. (2010) · Diabetologia · doi:10.1007/s00125-010-1750-8 · Cited by 165
Oxidative stress in non-insulin-dependent diabetes mellitus (NIDDM) patients
Ramakrishna, V., & Jailkhani, R. (2008) · Acta Diabetologica · doi:10.1007/s00592-007-0018-3 · Cited by 159
The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence
Nordin, C. (2010) · Diabetologia · doi:10.1007/s00125-010-1752-6 · Cited by 157
Intensified glucose lowering in type 2 diabetes: time for a reappraisal
Yudkin, J. S., Richter, B., & Gale, E. A. M. (2010) · Diabetologia · doi:10.1007/s00125-010-1864-z · Cited by 156
Insulin use and increased risk of mortality in type 2 diabetes: a cohort study
Gamble, J. ‐., Simpson, S. H., Eurich, D. T., Majumdar, S. R., & Johnson, J. A. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01125.x · Cited by 136
Westerbacka, J., Wilkinson, I., Cockcroft, J., Utriainen, T., Vehkavaara, S., & Yki-Järvinen, H. (1999) · Hypertension · doi:10.1161/01.hyp.33.5.1118 · Cited by 136
Insulin: Potential Negative Consequences of Early Routine Use in Patients With Type 2 Diabetes
Lebovitz, H. E. (2011) · Diabetes Care · doi:10.2337/dc11-s225 · Cited by 115
for the DIGAMI 2 Investigators, Mellbin, L., Malmberg, K., Norhammar, A., Wedel, H., & Rydén, L. (2011) · Diabetologia · doi:10.1007/s00125-011-2084-x · Cited by 114
Association between serious ischemic cardiac outcomes and medications used to treat diabetes
Margolis, D. J., Hoffstad, O., & Strom, B. L. (2008) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1630 · Cited by 104
A1C and Cardiovascular Outcomes in Type 2 Diabetes
Colayco, D. C., Niu, F., McCombs, J. S., & Cheetham, T. C. (2011) · Diabetes Care · doi:10.2337/dc10-1318 · Cited by 102
Clinical Practice Research Datalink (CPRD)
Gallagher, A. M., Kousoulis, A. A., Williams, T., Valentine, J., & Myles, P. (2021) · Springer Series on Epidemiology and Public Health · doi:10.1007/978-3-030-51455-6_3 · Cited by 86
The safety profile of exogenous insulin in people with type 2 diabetes: justification for concern
Currie, C. J., & Johnson, J. A. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01469.x · Cited by 54
Self-citationRensing, K. L., Reuwer, A. Q., Arsenault, B. J., von der Thüsen, J. H., Hoekstra, J. B. L., Kastelein, J. J. P., & Twickler, T. B. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01468.x · Cited by 49
Antoniades, C., Tousoulis, D., Marinou, K., Papageorgiou, N., Bosinakou, E., Tsioufis, C., Stefanadi, E., Latsios, G., Tentolouris, C., Siasos, G., et al. (2007) · Clinical Cardiology · doi:10.1002/clc.20101 · Cited by 41
Liebl, A., Jones, S., Benroubi, M., Castell, C., Goday, A., Aline Charles, M., Smith, H. T., Nicolay, C., & Simpson, A. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.555755 · Cited by 35
Dispensing patterns and financial costs of glucose‐lowering therapies in the UK from 2000 to 2008*
Currie, C. J., Peters, J. R., & Evans, M. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02849.x · Cited by 30
Self-citationVasculotoxic Effects of Insulin and Its Role in Atherosclerosis: What is the Evidence?
Nandish, S., Bailon, O., Wyatt, J., Smith, J., Stevens, A., Lujan, M., & CHILTON, R. J. (2011) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0165-4 · Cited by 22
Mbadi, A. N. J. N., Longo‐Mbenza, B., Muaka, M. M., Mbungu, F. S., & Lemogoum, D. (2009) · PubMed · Cited by 8
Cited by
Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)
Thakker, R. V., Newey, P. J., Walls, G. V., Bilezikian, J., Dralle, H., Ebeling, P. R., Melmed, S., Sakurai, A., Tonelli, F., & Brandi, M. L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1230 · Cited by 1,477
Francis, G. L., Waguespack, S. G., Bauer, A. J., Angelos, P., Benvenga, S., Cerutti, J. M., Dinauer, C. A., Hamilton, J., Hay, I. D., Luster, M., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0460 · Cited by 1,238
Low Wang, C. C., Hess, C. N., Hiatt, W. R., & Goldfine, A. B. (2016) · Circulation · doi:10.1161/circulationaha.116.022194 · Cited by 1,155
Gandini, S., Puntoni, M., Heckman-Stoddard, B. M., Dunn, B. K., Ford, L., DeCensi, A., & Szabo, E. (2014) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-13-0424 · Cited by 457
Ford, E., Carroll, J. A., Smith, H. E., Scott, D., & Cassell, J. A. (2016) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocv180 · Cited by 408
Metadata
- Authors
- Currie, C. J., Poole, C. D., Evans, M., Peters, J. R., & Morgan, C. L.
- Affiliations
- Cardiff University (GB)
- University Hospital of Wales (GB)
- Corresponding author
- Currie, Craig J.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2013-02-01
- Volume
- 98
- Issue
- 2
- Pages
- 668-677
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC3612791
- OpenAlex
- W2157836715
- Cited by
- 203
- References
- 38
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 9 · 2023: 5 · 2022: 7 · 2021: 15 · 2020: 17 · 2019: 15 · 2018: 25 · 2017: 18 · 2016: 26 · 2015: 23 · 2014: 19 · 2013: 12
- FWCI
- 21.02
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, insulin monotherapy, metformin, major adverse cardiac events, myocardial infarction, stroke, cancer risk, mortality, microvascular complications, renal complications, HbA1c, adverse drug reactions, primary care patients
- MeSH terms
- Adult, Aged, Aged, 80 and over, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Female, Humans, Hypoglycemic Agents, Insulin, Male, Metformin, Middle Aged, Prognosis, Retrospective Studies, Risk, Sulfonylurea Compounds, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.